EMA recommends marketing authorization for donanemab (Kisunla)
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
ADI submits World Health Assembly statement on COVID-19, dementia and future preparedness
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
The Davos Alzheimer’s Collaborative: A global preparedness plan for dementia
Davos Alzheimer's Collaborative (DAC) Co-chairs, Arnaud Bernaert and George Vradenburg, write about how DAC is building a coalition in order to accelerate Alzheimer's and dementia innovation.
ADI Council votes on new members, Board appointees
ADI is pleased to welcome 6 new member associations, as well as new members to the ADI board.
Medical and Scientific Advisory Panel (MSAP) meeting
During the 60-minute meeting, the advisory panel discussed ADI's activities over the last year, as well as proposals for future avenues of research, including a working group to explore the impact of COVID-19 as a potential risk factor for accelerating dementia.
ADI Council Meeting of 2021
The ADI Council met on 30 March 2021 to discuss ADI's activities over 2020, new membership applications and more.
ADI attends Western Pacific policy roundtable discussion
The discussions focused on developing a regional policy brief for the promotion, protection and restoration of mental health in older adults, with the inclusion of a focus on dementia awareness and risk reduction.
COSMIC: Investigating risk factors for dementia across different populations
Cohort Studies of Memory in an International Consortium
Eli Lilly presents results for Phase 2 TRAILBLAZER-ALZ trial for donanemab
Phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease.